Open AccessEfficacy and safety of adjuvant therapy with PD‑1/PD‑L1 inhibitors in cancer
Author(s) -
Dun-Chang Mo,
Ziyu Liang,
Long Chen,
Jianfeng Huang,
Peng-Hui Luo,
Han-Lei Wang
Publication year - 2022
Publication title -
experimental and therapeutic medicine
Language(s) - English
Resource type - Journals
eISSN - 1792-1015
pISSN - 1792-0981
DOI - 10.3892/etm.2022.11685
Subject(s) - medicine , nivolumab , atezolizumab , pembrolizumab , hazard ratio , oncology , adjuvant therapy , adverse effect , renal cell carcinoma , cancer , odds ratio , adjuvant , gastroenterology , immunotherapy , confidence interval